Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | M6PR | P20645 | 2/20 | 0.42 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.36 |
| ▸ | MGAM | O43451 | 4/20 | 0.34 |
| ▸ | SI | P14410 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13072839 | 0.97 | M6PR (0.46) | M6PRSYNJ2G6PDMEN1KMT2A | |
| SCHEMBL13929525 | 0.97 | M6PR (0.46) | M6PRSYNJ2G6PDMEN1KMT2A | |
| SCHEMBL12020014 | 0.87 | M6PR (0.37) | M6PRSYNJ2G6PDMEN1KMT2A | |
| SCHEMBL18023863 | 0.85 | M6PR (0.39) | M6PRSYNJ2G6PDMEN1KMT2A | |
| SCHEMBL12020066 | 0.85 | LGALS8 (0.41) | M6PRSYNJ2G6PDMEN1KMT2A | |
| SCHEMBL13126787 | 0.85 | M6PR (0.39) | M6PRSYNJ2G6PDMEN1KMT2A | |
| SCHEMBL8273427 | 0.84 | M6PR (0.40) | M6PRSYNJ2G6PDMEN1KMT2A | |
| SCHEMBL7208934 | 0.83 | M6PR (0.42) | M6PRSYNJ2G6PDMEN1KMT2A | |
| SCHEMBL10231826 | 0.83 | M6PR (0.42) | M6PRSYNJ2G6PDMEN1KMT2A | |
| SCHEMBL12820024 | 0.83 | M6PR (0.42) | M6PRSYNJ2G6PDLGALS8MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118515987-A | Functionalized hollow glass microsphere and preparation method thereof | 达州亮博新材料科技有限公司 | 2024-08-20 | — | — | CN | claimed |
| US-7728001-B2 | Opioid receptor ligands and methods for their preparation | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2010-06-01 | — | — | US | claimed |
| CN-118515987-A | Functionalized hollow glass microsphere and preparation method thereof | 达州亮博新材料科技有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-118515987-A | Functionalized hollow glass microsphere and preparation method thereof | 达州亮博新材料科技有限公司 | 2024-08-20 | — | — | CN | disclosed |
| US-9428494-B2 | Therapeutic compounds | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-08-30 | — | — | US | disclosed |
| CN-103911674-A | CELLULOSE CROSSLINKED FIBERS MANUFACTURED FROM PLASMA TREATED PULP | WEYERHAEUSER NR CO | 2014-07-09 | — | — | CN | disclosed |
| CN-102312384-B | Reduction of fiber knots of cellulose crosslinked fibers by using plasma pre-treated pulpsheets | WEYERHAEUSER NR CO | 2014-03-26 | — | — | CN | disclosed |
| US-8475631-B2 | Reduction of fiber knots of cellulose crosslinked fibers by using plasma pre-treated pulpsheets | Wyerhauser NR Company (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130137862-A1 | CELLULOSE CROSSLINKED FIBERS MANUFACTURED FROM PLASMA TREATED PULP | WEYERHAEUSER NR COMPANY (US) | 2013-05-30 | — | — | US | disclosed |
| CN-102312383-A | Tie the cellulose crosslinked fiber that reduces from the fiber of plasma treated pulp sheet production | WEYERHAEUSER NR CO | 2012-01-11 | — | — | CN | disclosed |
| CN-102312384-A | Use the pretreated pulp sheet material of plasma to reduce the fiber knot of cellulose crosslinked fiber | WEYERHAEUSER NR CO | 2012-01-11 | — | — | CN | disclosed |
| US-20120004406-A1 | CELLULOSE CROSSLINKED FIBERS WITH REDUCED FIBER KNOTS MANUFACTURED FROM PLASMA TREATED PULPSHEETS | WEYERHAEUSER NR COMPANY (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120000618-A1 | REDUCTION OF FIBER KNOTS OF CELLULOSE CROSSLINKED FIBERS BY USING PLASMA PRE-TREATED PULPSHEETS | WEYERHAEUSER NR COMPANY (US) | 2012-01-05 | — | — | US | disclosed |
| US-20100179217-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-7728001-B2 | Opioid receptor ligands and methods for their preparation | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2010-06-01 | — | — | US | disclosed |
| WO-2008055261-A2 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2006031782-A2 | SALVINORIN DERIVATIVES AS OPIOID RECEPTOR LIGANDS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20060058264-A1 | Opioid receptor ligands and methods for their preparation | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2006-03-16 | — | — | US | disclosed |
| US-4900324-A | HYDROXY ACETAL CELLULOSE CROSSLINKING AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1990-02-13 | — | — | US | disclosed |
| US-4900324-A | HYDROXY ACETAL CELLULOSE CROSSLINKING AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1990-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179217-A1 | THERAPEUTIC COMPOUNDS | OPRL1, OPRK1, OPRM1 | M6PR 288/4885SYNJ2 3325/4885G6PD 4018/4885 |
| US-20060058264-A1 | Opioid receptor ligands and methods for their preparation | OPRL1, OPRM1, OPRK1 | M6PR 125/4885SYNJ2 4477/4885G6PD 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.